ArticleBMJ open2026
Cognitive-behavioural therapy for insomnia in adults to decrease cannabis use: study protocol for a randomised controlled trial in a community sample of adults with frequent cannabis use.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05814822 (Targeting Insomnia to Improve Outcomes in Adults With Problematic Cannabis Use), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeting Insomnia to Improve Outcomes in Adults With Problematic Cannabis Use
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCannabis use is common in the USA and is associated with adverse outcomes across many domains, including sleep difficulties. Targeting insomnia with an evidence-based treatment could improve sleep and reduce frequent cannabis use. This randomised controlled trial (RCT) will compare evidence-based telemedicine-delivered cognitive-behavioural therapy for insomnia for adults with frequent cannabis use (CBTi-CB) against an active comparator, sleep hygiene education (SHE), for improving insomnia/sleep, associated daytime symptoms and cannabis use. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes. METHODS AND ANALYSIS: This is a single-site RCT with planned enrolment of 200 adults (21+ years of age) who meet criteria for both chronic insomnia and frequent cannabis use. Eligible participants will be randomised 1:1 to six sessions of CBTi-CB or SHE with clinical assessments conducted at pre-treatment, post-treatment and at 3 and 6 months post-treatment. Overnight polysomnography (PSG) will be conducted before and after treatment. Primary outcomes will include the Insomnia Severity Index, 12-item Short-Form Health Survey Mental Composite Score and cannabis use frequency as assessed by the interview-administered Timeline Follow Back. Electroencephalogram delta activity, derived from overnight PSG, will be the primary end point to assess the sleep homeostasis mechanism. ETHICS AND DISSEMINATION: Ethical approval for the study has been obtained from the Institutional Review Board of the University of Michigan Medical School (IRBMED #HUM00222302). The results of the investigation will be published in scientific papers. The data from the investigation will be made available through the National Institutes of Health (NIH) National Data Archive, which allows researchers on NIH grants to share and access raw data. TRIAL REGISTRATION NUMBER: NCT05814822.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.